CoChat

Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)

Frank, Rieke, Scheffler, Matthias, Merkelbach-Bruse, Sabine, Ihle, Michaela A., Kron, Anna, Rauer, Michael, Ueckeroth, Frank, König, Katharina, Michels, Sebastian, Fischer, Rieke, Eisert, Anna, Fassunke, Jana, Heydt, Carina, Serke, Monika, Ko, Yon-Dschun, Gerigk, Ulrich, Geist, Thomas, Kaminsky, Britta, Heukamp, Lukas C., Clement-Ziza, Mathieu, Büttner, Reinhard, Wolf, Jürgen · 2018 · Clinical Cancer Research
Cited by 167

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Purpose: KEAP1 and NFE2L2 mutations are associated with impaired prognosis in a variety of cancers and with squamous cell carcinoma formation in non–small cell lung cancer (NSCLC). However, little is known about frequency, histology dependence, molecular and clinical presentation as well as response to systemic treatment in NSCLC. Experimental Design: Tumor tissue of 1,391 patients with NSCLC was analyzed using next-generation sequencing (NGS). Clinical and pathologic characteristics, survival, and treatment outcome of patients with KEAP1 or NFE2L2 mutations were assessed. Results: KEAP1 mutations occurred with a frequency of 11.3% (n = 157) and NFE2L2 mutations with a frequency of 3.5% (n = 49) in NSCLC patients. In the vast majority of patients, both mutations did not occur simultaneously. KEAP1 mutations were found mainly in adenocarcinoma (AD; 72%), while NFE2L2 mutations were more common in squamous cell carcinoma (LSCC; 59%). KEAP1 mutations were spread over the whole protein, whereas NFE2L2 mutations were clustered in specific hotspot regions. In over 80% of the patients both mutations co-occurred with other cancer-related mutations, among them also targetable aberrations like activating EGFR mutations or MET amplification. Both patient groups showed different patterns of metastases, stage distribution and performance state. No patient with KEAP1 mutation had a response on systemic treatment in first-, second-, or third-line setting. Of NFE2L2-mutated patients, none responded to second- or third-line therapy. Conclusions: KEAP1- and NFE2L2-mutated NSCLC patients represent a highly heterogeneous patient cohort. Both are associated with different histologies and usually are found together with other cancer-related, partly targetable, genetic aberrations. In addition, both markers seem to be predictive for chemotherapy resistance. Clin Cancer Res; 24(13); 3087–96. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-3416

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 167

Metadata

Authors
Frank, R., Scheffler, M., Merkelbach-Bruse, S., Ihle, M. A., Kron, A., Rauer, M., Ueckeroth, F., König, K., Michels, S., Fischer, R., Eisert, A., Fassunke, J., Heydt, C., Serke, M., Ko, Y.-D., Gerigk, U., Geist, T., Kaminsky, B., Heukamp, L. C., Clement-Ziza, M., Büttner, R., & Wolf, J.
Venue
Clinical Cancer Research
Published
2018-07-01
Volume
24
Issue
13
Pages
3087-3096
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2795505616
Cited by
167
References
20
FWCI
15.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-3416
The paper
Frank, R., Scheffler, M., Merkelbach-Bruse, S., Ihle, M. A., Kron, A., Rauer, M., Ueckeroth, F., König, K., Michels, S., Fischer, R., Eisert, A., Fassunke, J., Heydt, C., Serke, M., Ko, Y.-D., Gerigk, U., Geist, T., Kaminsky, B., Heukamp, L. C., . . . Wolf, J. (2018). Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-3416

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.